NCT06476808 - A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

December 19, 2028

Study Completion Date

December 19, 2028

Conditions

High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

BMS-986463

Specified dose on specified days

Trial Locations (16)

20089

NOT_YET_RECRUITING

Local Institution - 0032, Rozzano

20141

NOT_YET_RECRUITING

Local Institution - 0033, Milan

31008

NOT_YET_RECRUITING

Local Institution - 0041, Avda.Pio XII 36,

33076

NOT_YET_RECRUITING

Local Institution - 0036, Borddeaux Cedex

43210

NOT_YET_RECRUITING

Local Institution - 0045, Columbus

69373

NOT_YET_RECRUITING

Local Institution - 0035, Lyon

75390

NOT_YET_RECRUITING

Local Institution - 0046, Dallas

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

94800

NOT_YET_RECRUITING

Local Institution - 0031, Villejuif

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

V5Z 4E6

RECRUITING

BC Cancer Vancouver, Vancouver

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université de Montréal, Montreal

H3T 1E2

RECRUITING

Jewish General Hospital, Montreal

08035

NOT_YET_RECRUITING

Local Institution - 0042, Barcelona